Successful rituximab treatment in IgG4-related coronary periarteritis: a case-based review
Rheumatology International · 2024
DOI: 10.1007/s00296-024-05774-3 ↗Kurz gefasst
Fallbericht in der Zeitschrift Rheumatology International, 2024. Verfasst von Koji Suzuki und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. …. Hauptthemen laut MEDLINE: Arteritis, Immunoglobulin G4-Related Disease, Rituximab. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
Immunoglobulin G4-related disease (IgG4-RD) is an immune-mediated disorder characterized by elevated serum IgG4 levels and the enlargement and fibrosis of organs. As a rare manifestation, coronary arteries can be affected by IgG4-RD as coronary periarteritis, leading to serious complications such as stenosis or aneurysm. Although coronary periarteritis poses a life-threatening condition, optimal treatment strategies remain unclear due to its extreme rarity. While glucocorticoids have shown efficacy in several reported cases of IgG4-related coronary periarteritis, many cases experience relapse during glucocorticoid tapering. Furthermore, long-term use of glucocorticoids promotes atherosclerosis and increases the risk of major adverse cardiovascular events. Given that rituximab has been reported to be effective in treating IgG4-RD, it may be a potential treatment option for this condition. We present a case of IgG4-related coronary periarteritis, in which the patient achieved and maintained remission with rituximab. Furthermore, our review of the literature identified 17 cases of IgG4-related coronary periarteritis, all of which were successfully treated with rituximab. These findings suggest that rituximab serves as a viable option for both induction and maintenance therapy in IgG4-related coronary periarteritis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. ksuzuki0418@keio.jp.
- Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
ORCID-Profile: Koji Suzuki, Mitsuhiro Akiyama, Hiroyuki Fukui, Yuko Kaneko
Zitieren
APA
Suzuki, K., Akiyama, M., Fukui, H., & Kaneko, Y. (2024). Successful rituximab treatment in IgG4-related coronary periarteritis: a case-based review. Rheumatology International. https://doi.org/10.1007/s00296-024-05774-3
Vancouver
Suzuki K, Akiyama M, Fukui H, Kaneko Y. Successful rituximab treatment in IgG4-related coronary periarteritis: a case-based review. Rheumatology International. 2024. doi:10.1007/s00296-024-05774-3
BibTeX
@article{Suzuki2024,
author = {Suzuki, Koji and Akiyama, Mitsuhiro and Fukui, Hiroyuki and Kaneko, Yuko},
title = {Successful rituximab treatment in IgG4-related coronary periarteritis: a case-based review},
journal = {Rheumatology International},
year = {2024},
doi = {10.1007/s00296-024-05774-3}
}
EUVIMED